Cargando…
Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients
Kidney transplant recipients are patients at high risk for coronavirus disease 2019 (COVID-19) due to being on immunosuppressive therapy. B cell depletion therapy, including rituximab, is an important strategy for ABO-incompatible transplants. However, knowledge about the effect of B cell depletion...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385485/ https://www.ncbi.nlm.nih.gov/pubmed/37515206 http://dx.doi.org/10.3390/v15071520 |
_version_ | 1785081419283824640 |
---|---|
author | Aida, Naohiro Ito, Taihei Kurihara, Kei Hiratsuka, Izumi Shibata, Megumi Suzuki, Atsushi Hasegawa, Midori Kenmochi, Takashi |
author_facet | Aida, Naohiro Ito, Taihei Kurihara, Kei Hiratsuka, Izumi Shibata, Megumi Suzuki, Atsushi Hasegawa, Midori Kenmochi, Takashi |
author_sort | Aida, Naohiro |
collection | PubMed |
description | Kidney transplant recipients are patients at high risk for coronavirus disease 2019 (COVID-19) due to being on immunosuppressive therapy. B cell depletion therapy, including rituximab, is an important strategy for ABO-incompatible transplants. However, knowledge about the effect of B cell depletion therapy on COVID-19 is lacking. Thirty kidney transplant recipients who developed COVID-19 were included in this study. To examine the impact of B cell depletion therapy, we retrospectively investigated the relationship between the background of the patients and the clinical outcome. Of the 30 patients, 13 received B cell depletion therapy. The median time between transplant and onset of COVID-19 was 6.1 years after transplantation; however, nine cases remained markedly depleted of CD19(+) cells (<4.0%). The patients were assigned to the normal (n = 21) and depletion groups (n = 9). Progression rates in the depletion and normal groups were 55.6% and 9.5%, respectively (p = 0.014). Furthermore, the survival rate was significantly lower in the depletion group (100% in the normal group vs. 66.7% in the depletion group; p = 0.021). B cell depletion therapy may have long-term effects and increase the risk of COVID-19 in kidney transplant recipients. |
format | Online Article Text |
id | pubmed-10385485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103854852023-07-30 Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients Aida, Naohiro Ito, Taihei Kurihara, Kei Hiratsuka, Izumi Shibata, Megumi Suzuki, Atsushi Hasegawa, Midori Kenmochi, Takashi Viruses Article Kidney transplant recipients are patients at high risk for coronavirus disease 2019 (COVID-19) due to being on immunosuppressive therapy. B cell depletion therapy, including rituximab, is an important strategy for ABO-incompatible transplants. However, knowledge about the effect of B cell depletion therapy on COVID-19 is lacking. Thirty kidney transplant recipients who developed COVID-19 were included in this study. To examine the impact of B cell depletion therapy, we retrospectively investigated the relationship between the background of the patients and the clinical outcome. Of the 30 patients, 13 received B cell depletion therapy. The median time between transplant and onset of COVID-19 was 6.1 years after transplantation; however, nine cases remained markedly depleted of CD19(+) cells (<4.0%). The patients were assigned to the normal (n = 21) and depletion groups (n = 9). Progression rates in the depletion and normal groups were 55.6% and 9.5%, respectively (p = 0.014). Furthermore, the survival rate was significantly lower in the depletion group (100% in the normal group vs. 66.7% in the depletion group; p = 0.021). B cell depletion therapy may have long-term effects and increase the risk of COVID-19 in kidney transplant recipients. MDPI 2023-07-07 /pmc/articles/PMC10385485/ /pubmed/37515206 http://dx.doi.org/10.3390/v15071520 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Aida, Naohiro Ito, Taihei Kurihara, Kei Hiratsuka, Izumi Shibata, Megumi Suzuki, Atsushi Hasegawa, Midori Kenmochi, Takashi Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients |
title | Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients |
title_full | Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients |
title_fullStr | Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients |
title_full_unstemmed | Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients |
title_short | Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients |
title_sort | impact of b cell depletion on covid-19 in kidney transplant recipients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385485/ https://www.ncbi.nlm.nih.gov/pubmed/37515206 http://dx.doi.org/10.3390/v15071520 |
work_keys_str_mv | AT aidanaohiro impactofbcelldepletiononcovid19inkidneytransplantrecipients AT itotaihei impactofbcelldepletiononcovid19inkidneytransplantrecipients AT kuriharakei impactofbcelldepletiononcovid19inkidneytransplantrecipients AT hiratsukaizumi impactofbcelldepletiononcovid19inkidneytransplantrecipients AT shibatamegumi impactofbcelldepletiononcovid19inkidneytransplantrecipients AT suzukiatsushi impactofbcelldepletiononcovid19inkidneytransplantrecipients AT hasegawamidori impactofbcelldepletiononcovid19inkidneytransplantrecipients AT kenmochitakashi impactofbcelldepletiononcovid19inkidneytransplantrecipients |